Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most common primary malignancy of bone in children, adolescents, and adults. Despite extensive surgery and adjuvant aggressive high-dose systemic chemotherapy with potentially severe bystander side effects, cure is attainable in about 70% of patients with localized disease and only 20%–30% of those patients with metastatic disease. Targeted therapies clearly are warranted in improving our treatment of this adolescent killer. However, a lack of osteosarcoma-associated/specific markers has hindered development of targeted therapeutics. We describe a novel osteosarcoma-associated cell surface antigen, ALCAM. We, then, create an engineered anti-ALCAM-hybrid polymerized liposomal nanoparticle immunoconjugate (α-AL-HPLN) to specifically target osteosarcoma cells and deliver a cytotoxic chemotherapeutic agent, doxorubicin. We have demonstrated thatα-AL-HPLNs have significantly enhanced cytotoxicity over untargeted HPLNs and over a conventional liposomal doxorubicin formulation. In this way,α-AL-HPLNs are a promising new strategy to specifically deliver cytotoxic agents in osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study demonstrated that ALCAM was associated with tumorigenesis in osteosarcoma [111].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [111]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647 · cited 1×
“Finally from a potential therapeutic delivery perspective, it is best when candidate tumor markers are internalized when bound by ligands or proteins at the cell surface [8].”
BackgroundLipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069 · cited 1×
“Liposomes, unilamellar vesicles composed of natural and/or synthetic lipids, have been a particularly intensively studied system [5].”
BackgroundHaran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934 · cited 1×
“Using this formulation, HPLNs were fabricated and their ability to be actively loaded with doxorubicin through generation of an ion gradient was assessed [21].”
MethodDetection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850 · cited 1×
“The use of diacetylene containing lipids to create polymerizable films and vesicles has been intensively studied for creating biosensors [25] and have been explored as cancer diagnostic and delivery vehicles [26].”
BackgroundAndresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580 · cited 1×
“This latter attribute has been particularly difficult to program into standard liposome formulations [6, 7].”
BackgroundSwart, G. W. M. (2002) · European Journal of Cell Biology · doi:10.1078/0171-9335-00256 · Cited by 251 · cited 1×
“This glycoprotein is a member of the immunoglobulin superfamily and is thought to mediate important cell-cell interactions involved in cell migration, neurogenesis, hematopoiesis, and the immune response [9].”
BackgroundOsteosarcoma of bone and its important recognizable varieties
Dahlin, D. C., & Unni, K. K. (1977) · The American Journal of Surgical Pathology · doi:10.1097/00000478-197701010-00007 · Cited by 234 · cited 1×
“This suggested that at the time of their initial diagnosis clinically undetectable tumor had already spread to distant sites in most patients and that effective systemic anticancer therapy was needed [2].”
BackgroundSequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
Janeway, K. A., & Grier, H. E. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70062-0 · Cited by 234 · cited 1×
“It is also now appreciated that exposure of pediatric cancer patients to cytotoxic chemotherapy can lead to secondary malignancies and other medical maladies, decades after their tumor has been eradicated [4].”
BackgroundIshida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., & Allen, T. M. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00409-6 · Cited by 216 · cited 1×
“The roughly 50-fold difference in IC50 between free doxorubicin and conventional liposomal doxorubicin seen in our osteosarcoma cell lines is consistent with that found in previously published model systems [22].”
Resultvan Kempen, L. C. L. T., van den Oord, J. J., van Muijen, G. N. P., Weidle, U. H., Bloemers, H. P. J., & Swart, G. W. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64943-7 · Cited by 204 · cited 1×
“For example, an increase in ALCAM expression is found in higher-stage more aggressive malignant melanoma [24].”
Background
Research works printed but not linked: 2
- Huvos AG Bone Tumors: Diagnosis, Treatment, and Prognosis 1991 Philadelphia, Pa, USA WB Saunders
- Gurney JG Swensen AR Bulterys M Malignant bone tumors Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995 1999 Bethesda, Md, USA SEER program, National Cancer Institute 99 110
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“The study demonstrated that ALCAM was associated with tumorigenesis in osteosarcoma [111].”
BackgroundNanotechnology in the targeted drug delivery for bone diseases and bone regeneration
Gu, Wu, Chen, & Xiao, Y. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44393 · Cited by 212
“nanoparticles, and over a conventional liposomal DXR formulation.(45) Besides, magnetic arsenic trioxide NPs were”
Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications
Madni, A., Sarfraz, M., Rehman, M., Ahmad, M., Akhtar, N., Ahmad, S., Tahir, N., Ijaz, S., Al-Kassas, R., & Löbenberg, R. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3cp55 · Cited by 176
“These polymerized liposomes are completely stable, provide modified release and enhance the half-life of therapeutic agents (186-188).”
BackgroundTargeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges
Gao, X., Li, L., Cai, X., Huang, Q., Xiao, J., & Cheng, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120404 · Cited by 180
Li, S., Zhang, T., Xu, W., Ding, J., Yin, F., Xu, J., Sun, W. Y., Wang, H., Sun, M., Cai, Z., et al. (2018) · Theranostics · doi:10.7150/thno.18299 · Cited by 157
“For example, activated leukocyte cell adhesion molecule (ALCAM) was thought to be a biomarker of osteosarcoma, and the DOX-loaded anti-ALCAM diabody hybrid polymer liposomal nanoparticle (α-ALCAM-HPLN/DOX) offered more toxicity toward osteosarcoma cells than the non-targeted HPLN/DOX [34].”
BackgroundDrug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
Hattinger, C. M., Patrizio, M. P., Fantoni, L., Casotti, C., Riganti, C., & Serra, M. (2021) · Cancers · doi:10.3390/cancers13122878 · Cited by 115
Antibody‐Incorporated Nanomedicines for Cancer Therapy
Wu, S., Wu, F., & Chen, X. S. (2022) · Advanced Materials · doi:10.1002/adma.202109210 · Cited by 102
Duchi, S., Sotgiu, G., Lucarelli, E., Ballestri, M., Dozza, B., Santi, S., Guerrini, A., Dambruoso, P. R., Giannini, S., Donati, D. M., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.012 · Cited by 97
Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
Masoumi, J., Jafarzadeh, A., Abdolalizadeh, J., Khan, H. Z., Jeandet, P., Mirzaei, H., & Mirzaei, H. R. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.015 · Cited by 90
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1147-6 · Cited by 75
Gazzano, E., Buondonno, I., Marengo, A., Rolando, B., Chegaev, K. Y., Kopecka, J., Saponara, S., Sorge, M., Hattinger, C. M., Gasco, A., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.029 · Cited by 67
Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives
Hegde, M., Naliyadhara, N., Unnikrishnan, J., Alqahtani, M. S., Abbas, M. A. E., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216066 · Cited by 58
Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence
Iram, S., Zahera, M., Wahid, I., Baker, A., Raish, M., Khan, A., Ali, N., Ahmad, S., & Khan, M. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-50215-y · Cited by 59
Pan, P., Yue, Q., Li, J., Gao, M., Yang, X., Ren, Y., Cheng, X., Cui, P., & Deng, Y. (2021) · Advanced Science · doi:10.1002/advs.202004586 · Cited by 51
Targeted nanomedicines for the treatment of bone disease and regeneration
Ordikhani, F., Zandi, N., Mazaheri, M., Luther, G. A., Ghovvati, M., Akbarzadeh, A., & Annabi, N. (2020) · Medicinal Research Reviews · doi:10.1002/med.21759 · Cited by 45
Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma
Ogiwara, Y., Nakagawa, M., Nakatani, F., Uemura, Y., Zhang, R., & Kudo‐Saito, C. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215690 · Cited by 44
CD177-mediated nanoparticle targeting of human and mouse neutrophils
Miettinen, H. M., Gripentrog, J. M., Lord, C. I., & Nagy, J. O. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200444 · Cited by 41
“In addition to the fusogenic peptides, the polymer content in the HPLN shell can be optimized to promote opening and nucleotide release [58].”
Self-citationCurrent status and future challenges of CAR-T cell therapy for osteosarcoma
Li, S., Zhang, H., & Shang, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290762 · Cited by 39
Microvessels-on-a-Chip to Assess Targeted Ultrasound-Assisted Drug Delivery
Park, Y. C., Zhang, C., Kim, S., Mohamedi, G., Beigie, C., Nagy, J. O., Holt, R. G., Cleveland, R. O., Jeon, N. L., & Wong, J. Y. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b09071 · Cited by 36
Self-citationNanocarrier-based drug delivery systems for bone cancer therapy: a review
Sekar, R. P., Kumar, T. S. S., & Jayakrishnan, A. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abf7d5 · Cited by 32
“Federman et al [67] developed hybrid liposomal NPs for specific targeting to osteosarcoma cells to deliver the anticancer agent DOX.”
CAR T targets and microenvironmental barriers of osteosarcoma
Zhu, J., Simayi, N., Wan, R., & Huang, W. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.12.010 · Cited by 33
Desai, S. A., Manjappa, A. S., & Khulbe, P. (2021) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-021-00059-3 · Cited by 28
Bao, Z., Zhang, C., Wang, H., Yan, W., Liu, Y., Li, M., & Zhang, W. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12118 · Cited by 28
Review of management issues in relapsed osteosarcoma
Nataraj, V., & Bakhshi, S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.863453 · Cited by 29
Yang, Y., Sanders, A. J., Dou, Q. P., Jiang, D. G., Li, A. X., & Jiang, W. G. (2021) · Cancers · doi:10.3390/cancers13205187 · Cited by 27
Xu, Y., Zhang, Z., Wang, H., Zhong, W., Sun, C., Sun, W., & Wu, H. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.629928 · Cited by 26
Brief review: Applications of nanocomposite in electrochemical sensor and drugs delivery
Khan, Z. U. H., Khan, T. M., Khan, A., Shah, N. S., Muhammad, N., Tahir, K., Iqbal, J., Rahim, A., Khasim, S., Ahmad, I., et al. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1152217 · Cited by 27
“Yan et al. (Federman et al., 2012) in 2004, combined the solgel technique and supramolecular surfactant techniques to synthesize a class of mesoporous bioactive glasses (MBG) to boost the bioactivity of traditional bioactive glass for bone repair by combining medication delivery with bioactive materials, their researc…”
MethodImmunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives
Mercatelli, D., Bortolotti, M., Bazzocchi, A., Bolognesi, A., & Polito, L. (2018) · Biomedicines · doi:10.3390/biomedicines6010019 · Cited by 25
“Antibody-targeted liposomal nanoparticles compared to non-targeted liposomal nanoparticles showed an increase in cytotoxicity for OS cells, ranging from two- to 23-fold, depending on liposomal formulation and the cell line tested [44].”
BackgroundChimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
Lin, Z., Wu, Z., & Luo, W. (2021) · Cancers · doi:10.3390/cancers13174469 · Cited by 21
Gormley, C. A., Keenan, B. J., Buczek‐Thomas, J. A., Pessoa, A. C. S. N., Xu, J., Monti, F., Tabeling, P., Holt, R. G., Nagy, J. O., & Wong, J. Y. (2019) · Langmuir · doi:10.1021/acs.langmuir.8b03692 · Cited by 19
Self-citationMaleki, M., Golchin, A., Alemi, F., Younesi, S., Asemi, Z., Javadi, S., Ali‐Khiavi, P., Soleinmapour, J., & Yousefi, B. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174131 · Cited by 19
Cancer cell targeting by CAR-T cells: A matter of stemness
D’Accardo, C., Porcelli, G., Mangiapane, L. R., Modica, C., Pantina, V. D., Roozafzay, N., Franco, S. D., Gaggianesi, M., Veschi, V., Iacono, M. L., et al. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1055028 · Cited by 19
“Physiologically, it regulates hematopoiesis, neurogenesis and inflammatory responses but it is also highly expressed and associated with tumorigenesis in many different tumors, such as breast, colorectal, prostate, melanoma, and pancreatic cancers (King et al., 2004; Federman et al., 2012).”
BackgroundCD166 and regulation of hematopoiesis
Chitteti, B. R., Bethel, M., Kacena, M. A., & Srour, E. F. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32836060a9 · Cited by 22
I3S/INEB, R. A. A., Alencastre, I. S., Sousa, D. M., Alves, C. J., Leitão, L. D. M., Neto, E., Aguiar, P., & Lamghari, M. (2016) · European Cells and Materials · doi:10.22203/ecm.v031a23 · Cited by 17
Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Yu, T., Jiang, W., Wang, Y., Zhou, Y. Y., Jiao, J., & Wu, M. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5628 · Cited by 14
“CD166 has been found in primary OS biopsy specimens, where its expression level is high (66).”
BackgroundBarzegari, A., Salemi, F., Kamyab, A., Aratikatla, A., Nejati, N., Valizade, M., Eltouny, E., & Ebrahimi, A. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100635 · Cited by 9
“Prior research has indicated that it is linked to the development of many different cancers, including osteosarcoma [153 – 156].”
Overall review of curative impact and barriers of CAR-T cells in osteosarcoma
Li, G., Wang, H., & Meftahpour, V. (2024) · EXCLI journal · doi:10.17179/excli2023-6760 · Cited by 8
Chen, B., Liu, Z., Zhang, J., Wang, H., & Yu, B. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s135396 · Cited by 6
“Federman et al have reported that CD166 is highly expressed in the osteosarcoma cell lines HOS, KHOS, KHOS240s, and SJSA, but its expression status is not observed in U2OS osteosarcoma cells.(54) They further proposed that this gene is a potential candidate for the targeted therapy of osteosarcoma.”
Li, S., Zhang, T., Xu, W., Ding, J., Yin, F., Xu, J., Sun, W. Y., Wang, H., Sun, M., Cai, Z., et al. (2020) · Theranostics · doi:10.7150/thno.46662 · Cited by 5
Biomaterial-Mediated Drug Delivery in Primary and Metastatic Cancers of the Bone
Forde, P. F., & Ryan, K. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-73664-8_20 · Cited by 4
Gao, H.-D., Hong, J.-L., Jian, C., Chen, T., Chang, N.-C., Meeroekyai, S., He, R., Liao, Y., Wang, C.-H., Su, C., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c21158 · Cited by 2
Targeted Nanoparticles: an Innovative Modality in the Treatment of CancerPreprint
Kang, H., Upton, B., Holly, R. W., Upton, R., Mitra, S. A., Parmentier, J., Mohrbacher, A., Kim, Y., Triche, T. J., & Nagy, J. O. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.01.691687 · Cited by 2
“The hollow shell particle is amenable to the addition of various targeting agents such as antibodies [4], diabodies [46], and peptides [73].”
InfluentialSelf-citationEmerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer
Ngema, L. M., Adeyemi, S. A., & Choonara, Y. E. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.077723 · Cited by 1
“A hybrid liposomal formulation for the delivery of doxorubicin was reported by Federman et al. [75], which exhibited specific targeting to osteosarcoma.”
Nanomedicine for the Treatment of Musculoskeletal Diseases
Ren, K., Wei, X. F., Zhang, L., & Wang, D. (2015) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3121-7_20 · Cited by 1
Terapia fotodinâmica em combinação com quimioterapia : uma opção no osteossarcoma
Brites, G. S. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Recent Advances in the Cancer Drug Delivery: Nanocarrier Approach
Prashar, D., & Poonam, P. (2021) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2021.v69i01.015
Introduction to Musculoskeletal Tissues and Drug Delivery Systems
Negi, A., Sharma, P., Mishra, V., & Murab, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-55653-1_1
Kang, H. G., Mitra, S. A., Upton, B., Parmentier, J. H., Hovsepyran, A., Nagy, J. O., & Triche, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.06.697855
Self-citationArfaoui, J., Ghorbel, A., Mathur, S., & Maleki, H. H. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00795
Current therapeutic interventions to target cancer stem cells for metastasis
Arora, P., Bhatia, R., Sharma, S., Sharma, A., Chauhan, S. C., Singh, J., & Sharma, A. K. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03154-4
“…or “Activated Leukocyte Cell Activated Molecule” (ALCAM), is a member of the immunoglobulin superfamily that is prominently expressed in multiple malignancies, such as prostate, colorectal, and osteosarcoma, and is linked to cancer stem cell traits, chemoresistance, and tumor suste-nance [126].”
Metadata
- Authors
- Federman, N., Chan, J., Nagy, J. O., Landaw, E. M., McCabe, K., Wu, A. M., Triche, T., Kang, H., Liu, B., Marks, J. D., & Denny, C. T.
- Affiliations
- Mattel Children's Hospital (US)
- NanoValent Pharmaceuticals Inc., Bozeman, MT 59718-4012, USA
- University of California, Los Angeles (US)
- University of Southern California (US)
- Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA
- University of California, San Francisco (US)
- Corresponding author
- Federman, Noah
- Venue
- Sarcoma
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-11
- ISSN
- 1357-714X (ISSN-L)
- 1369-1643
- PMC
- PMC3447386
- OpenAlex
- W4213018315
- Cited by
- 44
- References
- 30
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 5
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Sarcoma (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
- National Science Foundation (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- osteosarcoma, ALCAM, ALDH1, cell surface receptors, liposomal doxorubicin, targeted drug delivery, immunoconjugates, cytotoxicity, tumor growth inhibition, bone cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.